September 20, 2014 2:51 PM ET

Healthcare Providers and Services

Company Overview of Personal Genome Diagnostics, Inc.

Company Overview

Personal Genome Diagnostics, Inc. engages in the patient-specific analyses of cancer genome using digital characterization and monitoring technologies. The company provides METDetect Assay for the detection of MET gene amplifications in the circulation of cancer patients with reports that include identification and schematic representation of tumor-specific MET amplifications, annotation of predicted mutation consequences, data summary statistics, and integrated analysis reporting. Personal Genome Diagnostics, Inc. was founded in 2010 and is based in Baltimore, Maryland.

855 North Wolfe Street

Suite 629

Baltimore, MD 21205

United States

Founded in 2010

Phone:

410-558-1201

Fax:

410-522-5889

Key Executives for Personal Genome Diagnostics, Inc.

Co-Founder and Chief Medical Officer
Co-Founder and Chief Scientific Officer
Chief Financial Officer
Compensation as of Fiscal Year 2014.

Personal Genome Diagnostics, Inc. Key Developments

Personal Genome Diagnostics Inc. and Blueprint Medicines Disclose First-Ever Comprehensive Genomic Study of Malignant Mixed Mullerian Tumors

Personal Genome Diagnostics Inc. and Blueprint Medicines disclosed the first-ever comprehensive genomic study of malignant mixed Mullerian tumors (MMMT), an aggressive and deadly cancer of the female reproductive system, also known as carcinosarcoma. The new study, published in the current online edition of Nature Communications, uncovers genetic alterations previously not associated with MMMT. These genetic alterations likely play a role in development of the tumors and can serve as targets for anticancer drugs. Researchers from PGDx and Blueprint Medicines, with colleagues from Johns Hopkins University and Oregon Health and Science University, discovered that MMMT/carcinosarcomas have many mutations located in clinically relevant genes, such as PIK3CA, KRAS and DNA repair pathway genes. Some of these previously unidentified genetic mutations may be addressed by existing therapies or by investigational drugs currently in clinical trials. The analysis also revealed that a high fraction of mutations were in "chromatin remodeling" genes, which regulate the structure of chromosomes and, when mutated, are thought to have dramatic effects on the biology of the cell. Chromatin remodeling genes are currently being evaluated as potential targets for epigenetic and other novel therapies.

Appistry Teams with Personal Genome Diagnostics to Offer CancerSelect Test through Appistry CloudDx

Appistry, Inc. announced an agreement with Personal Genome Diagnostics to include the company's CancerSelect(TM) panel in Appistry's recently released Appistry CloudDx(TM) genomics testing service. PGDx is among the first organizations to offer lab-developed tests (LDTs) through Appistry's cloud-based service that makes LDTs from leading diagnostic test providers available to physicians across the United States. CancerSelect targets 120 genes of clinical and biological importance to cancer, providing information that can help physicians individualize treatment to a patient's cancer. The CancerSelect panel is sequenced in PGDx's CLIA-certified laboratory, and the analysis is conducted using PGDx's proprietary algorithms that provide extremely high coverage, copy number analyses for 63 genes, and translocation analysis for 17 genes. Appistry will collaborate with PGDx to deliver a report to participating physicians containing a pathological evaluation of the tumor sample; tumor-specific mutations (alterations and substitutions, amplifications, and translocations); a description of mutated genes and pathways along with biologic and clinical implications; full statistics; and therapeutic, predictive, and prognostic information and references, as well as referral information for ongoing clinical trials that might be relevant based on the analysis results. Appistry CloudDx streamlines and simplifies the workflow associated with genomics-based testing, which has been limited in its impact, partly because it requires organizations to amass infrastructure and expertise to deliver relevant results that are usable by physicians. Appistry CloudDx provides a single web dashboard for ordering and tracking the progress of tests and orchestrates the data flow between test providers such as PGDx and requesting physicians and hospitals, thereby ensuring that data and physical samples are transferred and securely managed in accordance with HIPAA and CLIA guidelines.

Personal Genome Diagnostics, Inc. Announces Launch of its METDetect(TM) Assay for the Detection of MET Gene Amplifications in the Circulation of Cancer Patients

Personal Genome Diagnostics, Inc. announced the launch of its METDetect(TM) Assay for the detection of MET gene amplifications in the circulation of cancer patients. Amplifications and other structural changes of the MET cancer gene have been associated with resistance to therapy and as major oncogenic drivers in a variety of tumors, including colorectal, lung, gastric, brain and head and neck cancer. PGDx's METDetect assay utilizes the company's PARE technology to uniquely identify structural alterations in the MET gene in circulating tumor DNA (ctDNA) directly from the patient's plasma, thereby eliminating the need for invasive and costly tumor biopsies. The METDetect test uses next generation sequencing (NGS) and PGDx's proprietary high sensitivity PARE and other technologies to identify focal amplifications of the MET gene that can be useful for prediction of therapeutic response, overall prognosis and cancer recurrence, and for ongoing monitoring. Analyses are performed in PGDx's CLIA laboratory certified for high complexity clinical testing and take two to three weeks. The comprehensive report includes identification and schematic representation of tumor-specific MET amplifications, annotation of predicted mutation consequences, data summary statistics and integrated analysis reporting. The METDetect assay is CLIA-approved and immediately available for clinical and investigative use.

Similar Private Companies By Industry

Company Name Region
Western Medical Supply, Incorporated United States
LifeWatch, Inc. United States
Fairmont Rehabilitation Center, LLC United States
East Houston Physician Surgical Services, Ltd, L.P. United States
Select Hospital Investors Inc United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
March 7, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Personal Genome Diagnostics, Inc., please visit personalgenome.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.